We are live on
!
Find out more
Arrowstreet Capital Portfolio holdings
AUM
$185B
1-Year Est. Return
39.58%
This Fund
S&P 500
This Quarter
Est. Return
+11.74%
1 Year Est. Return
+39.58%
3 Year Est. Return
+145.48%
5 Year Est. Return
+192.07%
10 Year Est. Return
+749.68%
AUM
$71.5B
AUM Growth
+$3.66B
(+5.4%)
Cap. Flow
-$2.85B
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
18.22%
Holding
1,538
New
294
Increased
526
Reduced
448
Closed
234
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$268M |
| 2 |
General Motors
GM
|
+$263M |
| 3 |
AstraZeneca
AZN
|
+$235M |
| 4 |
Vale
VALE
|
+$226M |
| 5 |
Oracle
ORCL
|
+$225M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$945M |
| 2 |
Microsoft
MSFT
|
+$606M |
| 3 |
Canadian Natural Resources
CNQ
|
+$552M |
| 4 |
Bank of America
BAC
|
+$490M |
| 5 |
AbbVie
ABBV
|
+$432M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.7% |
| 2 | Healthcare | 20.13% |
| 3 | Consumer Discretionary | 15.62% |
| 4 | Financials | 9.5% |
| 5 | Energy | 7.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
Bio-Rad Laboratories Class A
BIO
$9.42B
| $14.5M | 0.02% |
34,549
+1,521
| +5% | +$614K |
|
452
Enova International
ENVA
$6.39B
| $14.4M | 0.02% |
376,214
-3,133
| -0.8% | -$114K |
|
453
Credicorp
BAP
$30.3B
| $14.4M | 0.02% |
+106,119
| New | +$15M |
|
454
Encompass Health
EHC
$12.5B
| $14.4M | 0.02% |
240,668
-120,827
| -33% | -$6.57M |
|
455
CBIZ
CBZ
$2.96B
| $14.4M | 0.02% |
306,435
+4,460
| +1% | +$212K |
|
456
EXL Service
EXLS
$5.33B
| $14.3M | 0.02% |
420,815
-45,780
| -10% | -$1.59M |
|
|
FLG
457
Flagstar Bank National Association
FLG
$5.82B
| $14.3M | 0.02% |
552,508
-236,315
| -30% | -$6.33M |
|
458
Valley National Bancorp
VLY
$8.13B
| $14.2M | 0.02% |
1,257,387
-61,218
| -5% | -$721K |
|
459
Marvell Technology
MRVL
$189B
| $14.1M | 0.02% |
380,175
+367,731
| +2,955% | +$15M |
|
460
CoreCivic
CXW
$3.31B
| $13.9M | 0.02% |
1,205,074
+917,105
| +318% | +$10.2M |
|
|
DCH
461
Dauch Corp
DCH
$1.63B
| $13.9M | 0.02% |
1,781,321
+700
| +0% | +$6.27K |
|
462
DT Midstream
DTM
$13.9B
| $13.9M | 0.02% |
251,591
-91,620
| -27% | -$5.24M |
|
463
Open Text
OTEX
$5.89B
| $13.8M | 0.02% |
466,336
+372,296
| +396% | +$10.6M |
|
464
Patrick Industries
PATK
$2.78B
| $13.6M | 0.02% |
337,638
+12,333
| +4% | +$429K |
|
465
Embecta
EMBC
$289M
| $13.6M | 0.02% |
537,444
+75,096
| +16% | +$2.29M |
|
466
Dillards
DDS
$9.94B
| $13.6M | 0.02% |
41,964
+19,021
| +83% | +$6.19M |
|
467
Walt Disney
DIS
$179B
| $13.5M | 0.02% |
155,430
-3,351,196
| -96% | -$321M |
|
468
Brixmor Property Group
BRX
$9.12B
| $13.4M | 0.02% |
592,769
-290,553
| -33% | -$6.22M |
|
469
RLX Technology
RLX
$2.46B
| $13.4M | 0.02% |
5,838,674
+5,728,884
| +5,218% | +$10.2M |
|
470
Sinclair Inc
SBGI
$966M
| $13.2M | 0.02% |
851,043
-35,265
| -4% | -$627K |
|
471
Danaos Corp
DAC
$2.47B
| $13.1M | 0.02% |
249,091
-49,610
| -17% | -$2.79M |
|
|
EVRI
472
DELISTED
Everi Holdings
EVRI
| $13M | 0.02% |
902,832
-49,331
| -5% | -$820K |
|
473
Vista Energy
VIST
$7.52B
| $12.9M | 0.02% |
825,127
+21,900
| +3% | +$287K |
|
|
MASI
474
DELISTED
Masimo
MASI
| $12.8M | 0.02% |
86,229
+327
| +0.4% | +$45K |
|
475
NatWest
NWG
$76.2B
| $12.8M | 0.02% |
1,974,579
-1,370,293
| -41% | -$8.03M |
|
Similar funds
VGA
Arrowstreet Capital's Q4 2022 Portfolio in Review
As of Q4 2022, Arrowstreet Capital held 1,538 positions worth $71.5B, up 5.4% from $67.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Arrowstreet Capital withdrew a net $2.85B in Q4 2022, closing 234 positions and reducing 448 holdings. Its most notable exit was AbbVie, an estimated $432M position sold in full.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Arrowstreet Capital opened a new position in Gerdau worth $105M.
- Arrowstreet Capital's largest Q4 2022 buy was Gerdau: 23,855,591 shares worth $105M.
- Arrowstreet Capital added most to Visa in Q4 2022, an estimated $268M increase.
- Arrowstreet Capital's biggest Q4 2022 reduction was JPMorgan Chase, cutting an estimated $945M.
- Arrowstreet Capital fully exited AbbVie in Q4 2022, selling an estimated $432M.
- Arrowstreet Capital's ten largest holdings make up 18% of its $71.5B portfolio in Q4 2022.
- Arrowstreet Capital opened 294 new positions and closed 234 in Q4 2022.
- Arrowstreet Capital's portfolio value rose 5.4% quarter-over-quarter to $71.5B.
Based on Arrowstreet Capital's 13F filing for Q4 2022, filed 14 Feb 2023.